ANEMOCYTE

What can visual inspection reveal about manufacturing quality? Consistent inspection starts with an understanding of the product, its container, and the defects that may arise during manufacturing. In our latest article, we explore the AMClarity approach: risk assessment, tailored defect kits, microscopic characterization, and operator qualification. The article includes photographs of defect preparation and measurement, and considers how inspection data can guide process improvement. Read the article for a closer look at the process. #Anemocyte #AMCForward #BiotechInnovation

🇯🇵 BioJapan 2026 is just around the corner From October 7–9, Anemocyte will be in Yokohama for BioJapan 2026, connecting with the international biotech community at PACIFICO Yokohama. 📍 PACIFICO Yokohama – Exhibition Hall 📌 Partnering Area 04 Meet our team to discuss how Anemocyte can support your projects across: 🧬 Plasmid DNA development and manufacturing, from R&D to GMP 💉 mRNA development and manufacturing ⚙️ AMCAP™, our one-pot enzymatic capping technology for mRNA production BioJapan is an opportunity to meet in person, exchange perspectives on nucleic acid development and manufacturing, and explore potential collaborations. We will also be contributing to the scientific program with an Anemocyte talk: 🎤 Evolving Nucleic Acids Manufacturing: Scaling Clinical mRNA Synthesis via AMCAP One-Pot Technology 👤 Dr. Marco Pupo - Innovation & Development Coordinator 👤 Dr. Luca Frattini - Production Manager 📅 October 8 🕓 11:00 am The seminar is free to attend with registration. 👉 If you’re attending, connect with the Anemocyte team through the official partnering platform and schedule a meeting with us, following this link https://lnkd.in/et5jqBHP. #Anemocyte #AMCForward #BiotechInnovation #Plasmids #mRNA #BioJapan2026

Anemocyte has been shortlisted as a finalist for the CPHI Pharma Awards 2026 🏆 Our entry, “AMCAP™: Evolving the Enzymatic mRNA Manufacturing,” has been selected in the Manufacturing Excellence category. This recognition highlights the work behind AMCAP™, our proprietary one-pot enzymatic capping technology designed to simplify mRNA manufacturing while supporting high yield, capping efficiency, and process scalability. The winners will be announced during the CPHI Celebration Happy Hours: 📅 October 6, 2026 🕡 6:30–8:00 PM 📍 Supply and Formulation Excellence Theatre, Hall 2 If you’ll be attending CPHI Milan, we look forward to seeing you there. 👉 Register here: https://lnkd.in/euB6qukE #Anemocyte #AMCForward #BiotechInnovation #mRNA #MeetMeAtCPHIMILAN2026 #CPHIPharmaAwards

🧬 Accelerate Your CRISPR-Cas9 Research with AMCAP™ Cas9 mRNA For gene-editing workflows, transient Cas9 expression can offer an effective alternative to DNA-based delivery, limiting the duration of nuclease activity and reducing the risk of unintended genomic integration. AMCAP™ Cas9 mRNA is available off the shelf and ready to support research and preclinical development activities. Why choose it? ✅ High capping efficiency Designed with a Cap 1 structure to support mRNA stability and efficient translation. ✅ Optimized for eukaryotic expression Includes a 100A Poly(A) tail to replicate key features of mature eukaryotic mRNA. ✅ Flexible modification options Available in both unmodified and pseudouridine-modified versions. ✅ Rigorous quality control Produced in R&D grade, with optional analytical testing including CGE, LC-MS capping efficiency and Poly(A) analysis, residual dsRNA ELISA, endotoxin testing, and more. Key applications include: 🔹 precise gene editing and genome engineering 🔹 gene regulation studies 🔹 preclinical development for Cell & Gene Therapy programs 👉 Explore the full technical specifications and request a quote directly through our online shop: https://lnkd.in/dJ6UqSqr #Anemocyte #AMCForward #BiotechInnovation #mRNA

🧬 Overcoming the Immunogenicity Barrier One of the breakthroughs that made modern mRNA therapeutics possible was the use of modified nucleosides such as pseudouridine (Ψ) and N1-methylpseudouridine. Early synthetic mRNA molecules were often recognized by the innate immune system as foreign material. This could trigger inflammatory responses, accelerate RNA degradation and limit protein expression. Replacing standard uridine with modified nucleosides helped address these limitations in several ways: ✅ Reduced innate immune recognition Modified nucleosides can decrease activation of RNA-sensing pathways, helping the mRNA remain available for translation. ✅ Improved protein expression Greater molecular stability and more efficient interaction with the translation machinery can support higher and more consistent protein production. ✅ Longer functional persistence Increased resistance to cellular degradation can extend the duration of protein expression without the need to increase the administered dose. A small molecular modification helped transform synthetic mRNA into a practical platform for vaccines and a growing range of therapeutic applications. Anemocyte supports custom mRNA development and manufacturing with different nucleoside modification options, alongside a portfolio of off-the-shelf mRNA products. 👉 Explore our mRNA capabilities and available solutions: https://lnkd.in/d7kP9NyN #Anemocyte #AMCForward #BiotechInnovation #mRNA

🧬 Optimizing Lentiviral Vector Production: Why 3rd-Generation Plasmids Matter In lentiviral vector manufacturing, plasmid system design has a direct impact on safety, scalability and process performance. Third-generation lentiviral systems distribute the viral components across four plasmids, adding an extra layer of separation compared with earlier configurations. This architecture is widely used in research and clinical development because it supports a more controlled manufacturing strategy. Key advantages include: ✅ Enhanced safety profile Separating the rev gene onto an independent plasmid and using a Tat-independent 5′ LTR architecture helps reduce the risk of generating replication-competent lentivirus. ✅ High Scalability A well-designed plasmid system can support efficient transient transfection and consistent functional titers across development stages. ✅ Regulatory Compliance Using appropriate starting materials early helps simplify technology transfer and supports the transition from research to clinical manufacturing. Reliable plasmids are essential to keeping lentiviral vector programs on schedule. 👉 Explore Anemocyte’s off-the-shelf lentiviral plasmids and check availability: https://lnkd.in/dZ29k74k #Anemocyte #AMCForward #BiotechInnovation #Plasmids #LentiviralVectors #GeneTherapy